An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
Xencor, Inc. (NASDAQ:XNCR) announced the upcoming presentation of preclinical data on its XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The data aims to enhance T cell activation in solid tumors by targeting ligands that are typically absent in tumor cells. The platform focuses on noteworthy solid tumor targets such as CEACAM5, mesothelin, STEAP1, and Trop-2. This research reflects Xencor's commitment to advancing cancer therapies using its innovative XmAb technology, with an emphasis on the potential for increased efficacy in treating various solid tumors.
Positive
Presentation of promising preclinical data on XmAb CD28 bispecific antibodies.
Focus on innovative targets (CEACAM5, mesothelin, STEAP1, Trop-2) could lead to enhanced T cell activation.
Demonstrates Xencor's commitment to advancing cancer therapies.
Negative
None.
PASADENA, Calif.--(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
“T cells in the tumor microenvironment require engagement of their T cell receptor (TCR) and their co-stimulatory receptors like CD28 to achieve full activation. This is diminished in cancer because tumor cells usually do not express CD28 ligands. We have developed an XmAb antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement,” said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor. “We are using the platform to explore the universe of solid tumor targets, and at AACR we will present data on candidates targeting CEACAM5, mesothelin, STEAP1 and Trop-2, which have broad applicability across a range of solid tumors.”
Poster Presentation Details
Abstract 2983, “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors”
Session: Immunology – Therapeutic Antibodies 3
Date and Time: Monday, April 17, 2023, 1:30 p.m. - 5:00 p.m. EDT
Location: Poster Section 24, Board Number 30
Abstracts are available on AACR’s website located at www.aacr.org. Posters will be archived under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a proteins structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to, statements regarding research programs, the quotations from Xencor's senior vice president and chief scientific officer, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, in each case as described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2022 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
What is the purpose of Xencor's presentation at the AACR Annual Meeting 2023?
Xencor aims to present preclinical data on its XmAb CD28 bispecific antibody programs, focusing on enhancing T cell activation in solid tumors.
What are the key targets Xencor is focusing on for its bispecific antibodies?
The key targets include CEACAM5, mesothelin, STEAP1, and Trop-2, aimed at increasing effectiveness in treating solid tumors.
When will Xencor present its research at AACR 2023?
Xencor will present its research on April 17, 2023, during the Immunology – Therapeutic Antibodies 3 session.
How does Xencor's XmAb technology benefit cancer treatment?
XmAb technology allows for the rapid generation of drug candidates that can co-stimulate T cell activation specifically in the presence of tumor cells.
What implications does Xencor's research have for the market?
Successful outcomes from Xencor's preclinical studies may increase investor confidence and drive the company's stock performance in the biopharmaceutical sector.
